CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. is a clinical-stage biotech focused on age-related brain disorders, led by its oral p38α inhibitor neflamapimod. The drug is being developed primarily for dementia with Lewy bodies (DLB) without Alzheimer’s co-pathology, where there are currently no approved disease-specific treatments.
The company reports positive Phase 2a and 2b signals in DLB and alignment with the FDA on a single global Phase 3 trial using CDR-SB as the primary endpoint over 32 weeks in about 300 patients, subject to funding. Neflamapimod is also in Phase 2a studies for nonfluent primary progressive aphasia and recovery after ischemic stroke, and selected for evaluation in the EXPERTS-ALS platform trial.
CervoMed highlights manufacturing improvements to stabilize neflamapimod’s crystal form after earlier batch-related exposure issues, extensive nonclinical and human safety data with liver-enzyme monitoring, Fast Track designation in DLB, and Orphan Drug Designation in frontotemporal dementia. As of March 11, 2026, 9,258,719 shares of common stock were outstanding.
CervoMed Inc. announced completion of a Phase 1 healthy volunteer study evaluating a new, stable crystal form of its lead drug candidate neflamapimod and used the results to select the dose for its planned Phase 3 trial in dementia with Lewy bodies (DLB).
The company plans to use a 50mg three-times-daily regimen of the stable crystal form in Phase 3 to match the plasma drug levels associated with the clinically active batch from its prior RewinD-LB Phase 2b trial. Management highlights that a controlled manufacturing process now consistently produces the stable form, aiming to avoid past variability seen with less stable polymorphs.
CervoMed reiterates neflamapimod’s potential in DLB and other degenerative brain disorders based on earlier Phase 2 data and states it plans to initiate a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been selected for inclusion in the UK-based EXPERTS-ALS platform, which rapidly tests potential treatments for amyotrophic lateral sclerosis (ALS) using biomarker-based trials. This will be the first clinical evaluation of neflamapimod in ALS.
Neflamapimod, an oral small molecule that crosses the blood–brain barrier and selectively inhibits p38 MAP kinase, will initially be studied in approximately 35 ALS participants for 18–24 weeks, with possible expansion to up to 80 patients. The trial will measure changes in blood neurofilament light chain, a marker linked to neuroaxonal damage and ALS progression, and include clinical and survival endpoints.
Trial costs in EXPERTS-ALS are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, while CervoMed continues to focus on dementia with Lewy bodies (DLB) and plans a global Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options. On February 11, 2026, he was awarded options to acquire 30,000 shares of CervoMed common stock at an exercise price of $4.8 per share.
The award vests in 36 roughly equal monthly installments, with vesting starting on February 28, 2026 and continuing on the last calendar day of each month over three years. All 30,000 derivative securities are reported as directly owned following this grant.
CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire. A derivative position of 75,000 stock options with a $4.80 exercise price was granted on February 11, 2026 to her spouse, John Alam, the company’s President & Chief Executive Officer.
The options relate to 75,000 shares of common stock and were reported at a cost of $0 for the derivative itself, with 75,000 derivative securities beneficially owned after the transaction as indirect ownership "By Spouse." The filing states that Gregoire disclaims beneficial ownership. The underlying shares will vest in 36 monthly installments beginning February 28, 2026.
ELDER WILLIAM ROBERT reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
De Rosch Mark reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
Blackburn Kelly reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
ALAM JOHN J reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.
Morgan Stanley and its affiliate Morgan Stanley Capital Services LLC have filed a Schedule 13G reporting beneficial ownership of CervoMed Inc. common stock. Morgan Stanley reports beneficial ownership of 473,681 shares, representing 5.1% of CervoMed’s common stock as of the event date.
Morgan Stanley Capital Services LLC reports beneficial ownership of 470,631 shares, also representing 5.1% of the class, with shared voting and dispositive power over these shares. The filing states the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of CervoMed.